Catalyst Wire Dossier Catalyst Wire Dossier

KAND567

· Novakand Pharma AB
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KAND567, covering 2025-06-08 to 2025-06-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]

See pricing